• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2021 Jun 1;118(22):e2025759118.
doi: 10.1073/pnas.2025759118.
A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge


Zachary R Sia[SUP] 1 [/SUP], Xuedan He[SUP] 1 [/SUP], Ali Zhang[SUP] 2 [/SUP], Jann C Ang[SUP] 2 [/SUP], Shuai Shao[SUP] 1 3 [/SUP], Amal Seffouh[SUP] 4 [/SUP], Wei-Chiao Huang[SUP] 1 [/SUP], Michael R D'Agostino[SUP] 2 [/SUP], Amir Teimouri Dereshgi[SUP] 5 6 [/SUP], Sambhara Suryaprakash[SUP] 7 [/SUP], Joaquin Ortega[SUP] 4 [/SUP], Hanne Andersen[SUP] 8 [/SUP], Matthew S Miller[SUP] 9 [/SUP], Bruce A Davidson[SUP] 10 6 [/SUP], Jonathan F Lovell[SUP] 11 [/SUP]



Affiliations

Abstract

Recombinant influenza virus vaccines based on hemagglutinin (HA) hold the potential to accelerate production timelines and improve efficacy relative to traditional egg-based platforms. Here, we assess a vaccine adjuvant system comprised of immunogenic liposomes that spontaneously convert soluble antigens into a particle format, displayed on the bilayer surface. When trimeric H3 HA was presented on liposomes, antigen delivery to macrophages was improved in vitro, and strong functional antibody responses were induced following intramuscular immunization of mice. Protection was conferred against challenge with a heterologous strain of H3N2 virus, and naive mice were also protected following passive serum transfer. When admixed with the particle-forming liposomes, immunization reduced viral infection severity at vaccine doses as low as 2 ng HA, highlighting dose-sparing potential. In ferrets, immunization induced neutralizing antibodies that reduced the upper respiratory viral load upon challenge with a more modern, heterologous H3N2 viral strain. To demonstrate the flexibility and modular nature of the liposome system, 10 recombinant surface antigens representing distinct influenza virus strains were bound simultaneously to generate a highly multivalent protein particle that with 5 ng individual antigen dosing induced antibodies in mice that specifically recognized the constituent immunogens and conferred protection against heterologous H5N1 influenza virus challenge. Taken together, these results show that stable presentation of recombinant HA on immunogenic liposome surfaces in an arrayed fashion enhances functional immune responses and warrants further attention for the development of broadly protective influenza virus vaccines.

Keywords: adjuvant; cobalt porphyrin; influenza vaccine; liposomes; nanoparticle vaccine.
 
Back
Top Bottom